Global Injectable Drug Delivery Market Report 2013-2017
DUBLIN, Jan. 2, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/vxh8vv/injectable_drug) has announced the addition of the "Global Injectable Drug Delivery Market Report 2013-2017" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The injectable drug delivery formulation technologies segment accounted for the largest share of the overall injection drug delivery technologies market and is expected to at a CAGR of 16.3% from 2012 to 2017. This is due to surge of biologics and development of nanotechnologies. Based on product, the injectable drug delivery devices technologies market is further categorized into conventional injection devices, self injection devices, and others (microneedles, nanoneedles and blunt needle injections), while injectable drug delivery formulation technologies market is categorized into conventional drug delivery formulations and novel drug delivery formulations. Conventional injection devices segment accounted for the largest shareof the overall injectable drug delivery technologies market in 2012.
Furthermore, the market is segmented on the basis of its therapeutic applications such as auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, and Wilson's disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment). Hormonal disorders commanded the largest share of the global injectable drug delivery technologies market in 2012.
Key Topics Covered:
1 Introduction
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
2 Executive Summary
3 Market Overview
3.1 Introduction
3.2 Market Segmentation
3.3 Market Dynamics
3.4 Market Share Analysis, By Major Players
4 Global Injectable Drug Delivery Devices Technologies Market
4.1 Introduction
4.2 Market Segmentation
4.3 Manufacturers Criteria For Selection Of An Injectable Device
4.4 Conventional Injectable Drug Delvery Devices
4.5 Self-Injection Devices
4.6 Others
5 Global Injectable Drug Delivery Formulation Technologies Market
5.1 Introduction
5.2 Conventional Drug Delivery
5.3 Novel Drug Delivery Formulation Technologies
6 Global Injectable Drug Delivery Technologies Market, By Therapeutic Applications
6.1 Introduction
6.2 Auto-Immune Diseases
6.3 Hormonal Disorders
6.4 Orphan/Rare Diseases
6.5 Oncology
6.6 Others
7 Geographic Analysis
7.1 Introduction
7.2 North America
7.3 Europe
7.4 Asia-Pacific
7.5 Row
8 Competitive Landscape
8.1 Introduction
8.2 Expansion
8.3 Agreements, Partnerships, Collaborations & Joint Ventures
8.4 New Product Launch
8.5 Mergers & Acquisitions
8.6 Other Developments
8.7 Approvals
9 Company Profiles
Companies Mentioned:
- Alkermes, Inc
- Antares Pharma, Inc
- Baxter International, Inc
- Becton, Dickinson And Company
- Bespak Europe, Ltd (Subsidiary Of Consort Medical, Plc)
- Crossject
- Elcam Medical
- Eli Lilly And Company
- Gerresheimer Ag
- Haselmeier Gmbh
- Injex Pharma Gmbh (Subsidiary Of Hns International, Inc)
- Novo Nordisk A/S
- Owen Mumford, Ltd
- Sanofi
- Schott Ag
- Shl Group
- Terumo Corporation
- Unilife Corporation
- Vetter Pharma-Fertigung Gmbh & Co Kg
- West Pharmaceutical Services, Inc
- Ypsomed Holding Ag
- Zogenix
For more information visit http://www.researchandmarkets.com/research/vxh8vv/injectable_drug
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article